Biogen grows immunology and rare disease portfolio with Apellis buyout
Biogen has revealed it will acquire Apellis Pharmaceuticals for an upfront payment of approximately $5.6 billion and a contingent value right (CVR) per share payable upon achievement of certain thresholds. Apellis stockholders will receive two payments of $2 per share each, contingent on certain annual global net… Read More